Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388973 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
NCT00388973 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 338 participants.
The verdict
NCT00388973, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388973
The ClinicalTrials.gov registry entry for NCT00388973 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT00388973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388973 about?
NCT00388973 is a clinical study titled "Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder". The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major depressive disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the...
What is the current status of trial NCT00388973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2006-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00388973?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00388973?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.